Varicent Honors Standout Partners Driving the Future of Sales Performance Management
Article content
TORONTO — Varicent, a global leader in sales performance management (SPM), announced the winners of its annual Partner Awards at its Accelerate 2025 conference held two weeks ago. These awards recognize the organizations turning strategy into real-world results and shaping the future of SPM.
Article content
Article content
'At Varicent, we believe great outcomes come from great execution, and great execution takes great partners,' said Jason Loh, Chief Growth Officer at Varicent. 'This year's winners didn't just support our clients; they advanced them. Together, we're helping organizations turn bold strategies into lasting results.'
Article content
This year's winners brought fresh ideas, broke down barriers, and delivered measurable impact:
Article content
Deloitte opened critical conversations with executive stakeholders and ensured that Varicent solutions were part of global transformation initiatives. Their focus on certification and delivery readiness helped accelerate deployment timelines and deliver faster outcomes across multiple regions.
Article content
North America Partner of the Year: ZS
Article content
ZS delivered outstanding results across Sales Planning initiatives. They helped enterprise clients rethink their planning processes, uncovered new revenue opportunities, and led large-scale transformations that improved forecasting accuracy and sales effectiveness.
Article content
Joint Impact Award: Argano
Article content
Argano played a hands-on role throughout the sales cycle, joining discovery sessions, participating in demos, and helping customers navigate critical decisions. Their collaboration directly contributed to closing key deals and accelerating project starts.
Article content
OpenSymmetry focused on making customer success a competitive advantage. They deployed experienced teams to support faster go-lives and higher adoption rates, and they introduced new global learning forums that helped customers realize more value from their solutions.
Article content
Accenture brought new enterprise opportunities to the table and worked side by side with sales teams to build strong business cases. Their direct involvement helped win competitive deals and positioned Varicent's solutions as critical to strategic initiatives.
Article content
Innovation Partner of the Year: KPMG
Article content
KPMG provided actionable insights that shaped both product strategy and delivery. They worked closely with customers to solve complex implementation challenges, ensuring that Varicent's solutions addressed both immediate needs and long-term growth plans.
Article content
Breakthrough Partner Award: Workday
Article content
Workday created new pathways for collaboration between sales and operations teams. Their early involvement in customer planning cycles led to faster solution deployment and measurable efficiency improvements in key accounts.
Article content
Varicent delivers market-leading SaaS software solutions that empower revenue leaders to drive growth. Its solutions are designed to help customers design, amplify, and optimize go-to-market strategies that create a connected path to revenue. Organizations worldwide leverage Varicent's solutions to set smart goals and territories that maximize revenue potential, use AI-driven insights to make proactive commercial decisions, and create incentive programs that amplify the sales strategy and achieve revenue goals. To learn more about Varicent, visit www.varicent.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less or retire earlier than planned. Money doesn't buy happiness, but being less dependent on work to fund your lifestyle could be a contributor to a happier, less stressful life. A great way to build up dividend income is to invest in high-yielding dividend stocks that also happen to be lower-risk investments. Pfizer (NYSE: PFE), Realty Income (NYSE: O), and Bank of Nova Scotia (NYSE: BNS) are three attractive investments that you'll want to consider if you want to create a strong portfolio of income-generating stocks. Pfizer If you're looking for a high-yielding stock to hold for the long term, Pfizer is one you'll want to strongly consider. At 7.4%, its yield right now is more than five times what you'd get with the average stock on the S&P 500, which pays about 1.3%. Pfizer's stock is trading down more than 10% this year (as of the end of last week), as it can't seem to catch a break. While its valuation is modest -- it trades at 17 times its trailing earnings -- concerns about healthcare reform and the company's future growth prospects have made investors uneasy about the business and investing in it. But the healthcare company is still doing well and is on track to hit its guidance, which calls for revenue between $61 billion and $64 billion this year (comparable to how it did last year). It is also slashing costs to improve its bottom line. And it has been less than two years since it acquired oncology company Seagen, which may unlock more long-term growth for Pfizer in the future. Last year, the company also obtained approval from regulators for its first gene therapy in the U.S. -- Beqvez, a treatment for a genetic bleeding disorder. There's some uncertainty and risk with Pfizer, but there are opportunities as well. And at such a modest valuation, now can be an excellent time to add it to your portfolio. Pfizer has been a big name in healthcare for decades, and I don't think that's likely to change anytime soon. Realty Income One dividend stock I think all income investors should consider owning is Realty Income. This is a real estate investment trust (REIT) that not only offers a high yield of 5.8%, but it also pays a dividend every month. There's no need to wait around for multiple months, as is the case with other dividend stocks; with Realty Income, you're getting a much more regular stream of cash flow. The REIT has a diverse mix of tenants, which makes it an ideal option for long-term investors. It's diversified across industries and geographies, with more than 1,500 clients across 91 industries. The dividend remains well supported -- the REIT reported funds from operations (FFO) per share of $1.05 during the first three months of the year (versus $0.94 a year ago). That averages out to $0.35 per share per month, which is higher than the rate of its monthly dividend of $0.2685. REITs use FFO to assess how much they can afford to pay in dividends, and with Realty Income's financials looking solid, there aren't any significant risks with its payout. Share prices of Realty Income are up 5% this year, and this can be a great income-generating investment to add to your portfolio for the long haul. Bank of Nova Scotia Rounding out this list of high-yielding dividend stocks is Canada-based Bank of Nova Scotia, also known as Scotiabank. At around 6%, that's a high payout for a top bank stock that is known for long-term stability. It declared its first dividend back in 1833 and has continued making regular payments since then. The bank increased its provision for credit losses in its most recent quarter, in a sign of growing concern about macroeconomic conditions. Scotiabank's net income totaled over $2 billion Canadian dollars for the period ending April 30, which was nearly identical to its bottom line in the prior-year period. There are concerns about how the Canadian economy may perform in the near future due to tariffs, but in the grand scheme of things, that may prove to be a short-term concern for investors who are willing to hang on for years. Scotiabank's impressive track record and resilience over the years should inspire some confidence in the business. The bank stock has increased its dividend by more than 22% in four years and can be an excellent option to hang on to for the long term. Not only can you collect a high yield today, but the dividend income you get from this investment can rise over the years. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
20 minutes ago
- Globe and Mail
As gas cars began to hit the streets of Toronto, the city was already an EV manufacturing hub
Dumaresq de Pencier is the exhibit and project coordinator for the Canadian Automotive Museum in Oshawa, Ont. While Tesla may be credited with popularizing modern electric vehicles, they are far from being the first to develop an EV. And I'm not talking about General Motors's EV1 from 1996. EVs appeared decades before the first gas-powered car, going back nearly 200 years. And around the time gas cars began hitting the streets of Toronto the city was already an EV manufacturing hub. From 1893 to 1913, four Canadian companies and one American company built or tried to build electric vehicles in the Greater Toronto Area. Two of these companies still exist, though most people likely wouldn't recognize them today. In an era when gasoline engines were a novelty and steam power was inconvenient for automobile use, electrics were the next big thing. British engineer William Joseph Still was an inventor of steam and electrical technologies whose patent batteries sold well on both sides of the Atlantic in the 1890s. In 1893, he approached Toronto patent lawyer Frederick Barnard Fetherstonhaugh with a new lightweight battery design. The two had already worked together for several years and Fetherstonhaugh, a tinkerer and inventor himself, thought the new battery would be perfect for an electric automobile. Fetherstonhaugh worked with Still and the Toronto-based Dixon Carriage Company at the corner of Bay and Temperance Streets to build the car. It was a 320-kilogram technological marvel that could manage an hour of driving at 24 kilometres an hour. This speed was comparable or even slightly faster than most passenger cars being introduced at the time. Fetherstonhaugh used it as his daily driver for 15 years, charging it at his home in southwest Toronto neighbourhood of Mimico and demonstrating it at the Canadian National Exhibition in 1893, 1896 and 1906. The vehicle vanished from the historical record after the 1912 Toronto Auto Show. In 1897, Still established the Canadian Motor Syndicate to build and sell his car designs. The company's first vehicle was an electric delivery tricycle, shown at the 1898 Canadian National Exhibition. By 1899, Still had invented a more efficient electric motor, better suited for large vehicles. His business was reorganized as the Still Motor Company Limited (SMC) and began selling vehicles in earnest. Its factory on Yonge Street was a hive of activity, helped by one of the City of Toronto's first commercial telephone lines. SMC generally didn't build vehicles from scratch; clients brought them commercial carriages, which the factory retrofitted with motors and batteries. Parker's Dye Works (known today as Parker's Dry Cleaning) was an early adopter and, by 1900, many of Toronto's biggest industrial and commercial concerns had at least one or two SMC vehicles in their fleets. SMC electrics were light, reasonably fast and easy to control, but almost all of them were custom jobs, resulting in high costs and low profits for the company. Financial support came in the form of a buyout from a group of British investors who renamed the company Canadian Motors Limited (CML). In late 1899, Still had developed a moderately successful line of two- and four-seater passenger electrics: the Ivanhoes and the Oxfords. The new owners wanted to sell them in England and CML became the first British-owned car company in Canada and Canada's first car exporter. The company sent dozens of vehicles to England in late 1900 and early 1901, but CML's success in British road trials didn't equate to sales. By 1904, the organization was shuttered on both sides of the Atlantic and Still had moved on to other more lucrative projects. The CML factory in Toronto didn't remain closed for long. In 1903, it was bought by bicycle manufacturing conglomerate Canadian Cycle & Motor Company, which turned it over to the manufacturer of an American electric car, also named the Ivanhoe. These vehicles never sold well and in 1905 the company dropped the brand to focus primarily on gasoline cars. A small side business making hockey equipment under the brand 'CCM' would prosper and still exists today. These Canadian manufacturers had competition. The Fischer Equipment Company of Chicago demonstrated its twin-engine Woods Electric cars and trucks in Toronto in 1898, gaining so much interest that by 1899 the whole enterprise had reorganized as the Woods Motor Vehicle Company. This company had a mostly Canadian board of directors that included representatives from Canadian General Electric, the Dominion Bank and Canadian Pacific Railways. Woods cars were planned to be built at the General Electric plant in Hamilton, which would provide Toronto with an electric taxi network. Woods shifted its focus south of the border in 1901 and kept producing electrics in the U.S. until 1918. Canadian demand for electric cars continued. In 1911, the wealthy McLaughlin Motorcar Company of Oshawa began marketing luxury electric cars on the American Rauch & Lang chassis across southern Ontario. There were plans to build the cars in 1912, but it is unclear if those plans materialized. Within a few years, McLaughlin would become General Motors Canada, though the company has yet to attempt EV production in Oshawa a second time. A smaller-scale local contender was the Peck electric, built on Jarvis Street and marketed at the 1912 Auto Show as the car that 'Keeps Pecking.' Despite cushy interiors, easy-to-use controls and lavish colour ads in the pages of Motoring Magazine, the car's whopping $4,000 sale price – more than $109,000 in today's dollars – was a deterrent, and the company folded in 1913. It would take around a century, and dramatic improvements in technology, for EVs to return to Toronto. Still, every electric car driven on our streets today forms the latest link in a chain that extends back in time more than a century to the era of steam and brass.
Globe and Mail
22 minutes ago
- Globe and Mail
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. 1. Most of the company's problems should be temporary I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. 2. The two biggest threats to UnitedHealth Group are iffy I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. 3. The price is right Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
